Analysis of prognostic factors for survival in the Russian population of patients with disseminated gastric cancer, who received ramucirumab as secondline therapy in the RAMSELGA trial

Background. Ramucirumab is a monoclonal antibody that inhibits the vascular endothelial growth factor receptor-2 (VEGFR2). The study is aimed to analyse prognostic factors for survival in patients with disseminated gastric cancer who received ramucirumab in the second-line therapy in ’real-life’ cli...

Повний опис

Бібліографічні деталі

Автори:	N. S. Besova, T. A. Titova, Е. V. Artamonova, A. A. Tryakin, D. L. Stroyakovskiy, E. V. Perminova, D. Yu. Yukalchuk, D. M. Ponomarenko, N. P. Belyak, R. V. Orlova, G. M. Teletaeva, E. Yu. Ratner, A. S. Mochalova, O. O. Gordeeva, A. S. Zhabina, S. V. Gamayunov, A. V. Smolin, A. Yu. Povyshev, M. I. Andrievskikh, I. S. Stilidi
Формат:	Artigo
Мова:	Russo
Опубліковано:	Remedium Group LLC 2020-07-01
Серія:	Медицинский совет
Предмети:	gastric cancer second line ramucirumab prognostic factors paclitaxel irinotecan
Онлайн доступ:	https://www.med-sovet.pro/jour/article/view/5720
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!